newsfilter
← Latest News
GlobeNewswire·

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson's Disease, Including Over 3 More Hours of Daily "Good On" Time When Switching from RYTARY®

Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groupsDemonstrated substantial increases in daily "Good On" time, reductions in "Off"